SCHEMBL6820989

SCHEMBL6820989

COCCOc1c(C2=NCCN2)cc2ccccc2c1-c1ccccc1OC

nearest known ligand 0.54

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 6/20 0.54
PDCD1LG2 Q9BQ51 4/20 0.40
CD274 Q9NZQ7 4/20 0.40
MC4R P32245 1/20 0.38
KCNH2 Q12809 1/20 0.38
GPR84 Q9NQS5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7736372 0.99 NISCH (0.53) NISCHPDCD1LG2CD274MC4RKCNH2
Hydrochloric Acid SCHEMBL7736753 0.88 NISCH (0.53) NISCHPDCD1LG2CD274
Hydrochloric Acid SCHEMBL7736687 0.87 NISCH (0.52) NISCHPDCD1LG2CD274KCNH2
Hydrochloric Acid SCHEMBL7735623 0.87 NISCH (0.52) NISCHPDCD1LG2CD274MC4R
Hydrochloric Acid SCHEMBL7738710 0.86 NISCH (0.53) NISCHPDCD1LG2CD274MC4RKCNH2
SCHEMBL6820917 0.85 NISCH (0.52) NISCHPDCD1LG2CD274GPR84
Hydrochloric Acid SCHEMBL7736772 0.84 NISCH (0.49) NISCHPDCD1LG2CD274KCNH2
Hydrochloric Acid SCHEMBL7736784 0.84 NISCH (0.51) NISCHPDCD1LG2CD274GPR84
SCHEMBL6826675 0.84 NISCH (0.51) NISCHPDCD1LG2CD274
Hydrochloric Acid SCHEMBL7738672 0.84 NISCH (0.53) NISCHPDCD1LG2CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US claimed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP claimed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 WO claimed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP claimed
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US disclosed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 WO disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R NISCH 277/4885PDCD1LG2 4073/4885CD274 4124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.